Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC)
| العنوان: | Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC) |
|---|---|
| المؤلفون: | Arno Amann, Finn Mildner, Maria Theresia Kasseroler, Marcel Kloppenburg, Daniel Dejaco |
| المصدر: | memo - Magazine of European Medical Oncology. 13:395-399 |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Chemotherapy, medicine.medical_specialty, Performance status, business.industry, medicine.medical_treatment, Head and neck cancer, Cancer, Hematology, Pembrolizumab, medicine.disease, Head and neck squamous-cell carcinoma, law.invention, 03 medical and health sciences, Regimen, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, 030215 immunology |
| الوصف: | Recurrent and metastatic squamous cell carcinomas of the head and neck are still difficult to treat. The EXTREME regimen has been the standard of care for the last decade, but recent studies initiated a change. In this work we provide an overview of the established treatment concepts for recurrent and metastatic squamous cell carcinomas of the head and neck with palliative intent. We performed a literature search using the key words: recurrent, metastatic, cancer, head and neck, HNSCC, treatment, chemotherapy, immunotherapy, salvage, and surgery. Furthermore, the presentations of the ASCO highlights of head and neck cancer from 2019 and 2020 were included. The KEYNOTE-048 and the TPEx randomized trial are the most relevant trials in the first line setting. The CheckMate 141 and KEYNOTE-040 have the greatest impact for the second line regimen. The expression of PD-L1, prior treatment, performance status, local symptoms and tumor burden are the most important factors regarding choice of treatment. Pembrolizumab alone or in combination with chemotherapy can be recommend as the 1st line standard in patients with combined positive score (CPS) ≥20. The choice of therapy in patients with CPS 1-19 and CPS |
| تدمد: | 1865-5076 1865-5041 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::a60184b207f1525a26b10928fe68e9ce https://doi.org/10.1007/s12254-020-00645-6 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........a60184b207f1525a26b10928fe68e9ce |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 18655076 18655041 |
|---|